Document is current
Any future updates will be listed below
-
Authors
Matsumura, Takayuki http://orcid.org/0000-0003-1760-3484
Nishiyama, Ayae
Aiko, Michio
Ainai, Akira
Ikebe, Tadayoshi
Chiba, Joe
Ato, Manabu
Takahashi, Yoshimasa
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20fk0108130)
Japan Society for the Promotion of Science (JP20K08833)
Takeda Science Foundation
- License Information
-
More Information
Article History
Received: 15 May 2020
Accepted: 1 September 2020
First Online: 5 September 2020
Ethics approval and consent to participate
: This study protocol was approved by the National Institute of Infectious Diseases Ethic Review Board for Human Subjects (Permit number: 756) and the animal experiments were approved by the National Institute of Infectious Diseases Animal Experiments Committee (Permit numbers: 116044, 118014). All participants provided written informed consent in accordance with the Declaration of Helsinki. All animal experiments were performed according to the Guide for Animal Experiments Performed at National Institute of Infectious Diseases, Japan.
: Not applicable.
: TM., J.C., M.Ato, and Y.T. have filed a patent application for antibodies HS1, HS2, and HS3 with the National Institute of Infectious Diseases.
